Clinical Scorecard: When to Treat First in Metastatic NSCLC?

At a Glance

Key Highlights

• Both upfront and delayed LRT combined with ICI result in a 3-year overall survival of about 45%.
• Median overall survival was 26 months in the upfront LRT cohort and 25 months in the upfront ICI cohort.
• Favorable prognostic factors include good performance status, non-squamous histology, and high PD-L1 expression.
• No clear survival signal emerged to suggest superiority of one sequencing approach over the other.
• Patient and disease characteristics are dominant drivers of outcomes.

Guideline-Based Recommendations

Diagnosis

• Evaluate patients for synchronous oligometastatic NSCLC without actionable genomic alterations.

Management

• Consider both upfront and delayed LRT combined with ICI based on individual patient characteristics.

Monitoring & Follow-up

• Monitor overall survival and progression-free survival as key endpoints.

Risks

• Be aware of potential early progression, treatment toxicity, and evolving goals of care that may prevent planned local therapy.

Patient & Prescribing Data

Patients with synchronous oligometastatic NSCLC and no actionable genetic alterations.

Flexibility in sequencing treatment based on disease biology, performance status, PD-L1 expression, and patient preferences is crucial.

Clinical Best Practices

• Engage in multidisciplinary decision-making for treatment planning.
• Individualize care based on patient characteristics and preferences.
• Acknowledge the limitations of retrospective analyses when interpreting outcomes.

Related Resources & Content

• Lung Cancer